Jazz Pharmaceuticals plc is a dynamic specialty biopharmaceutical company that identifies, develops and commercializes innovative products to address unmet medical needs in focused therapeutic areas, always keeping in mind our mission to improve patients’ lives. Our unwavering commitment to advancing patient care is demonstrated every day. Living our core values of integrity, passion, collaboration, innovation and the pursuit of excellence is the key to our success. Headquartered in Dublin, Ireland with locations in California and Pennsylvania, the company is committed to working closely with patients, patient advocacy groups and healthcare professionals. Jazz Pharmaceuticals markets a diverse portfolio of products in the areas of narcolepsy, oncology, pain and psychiatry.
Webcast ImageWebcast
Jazz Pharmaceuticals at Cantor Fitzgerald Healthcare Conference (Live)
07/08/15 at 9:30 a.m. ET
Press Releases
Jul 01 2015 - 4:05 p.m.
Jazz Pharmaceuticals to Present at Cantor Fitzgerald Healthcare Conference on July 8
Jun 08 2015 - 9:06 a.m.
Jazz Pharmaceuticals Announces First Patients Enrolled in Phase 3 Clinical Development Program Evaluating JZP-110 as a Potential Treatment of Excessive Daytime Sleepiness (EDS) Associated with Narcolepsy or with Obstructive Sleep Apnea (OSA)
Jun 04 2015 - 9:06 a.m.
Jazz Pharmaceuticals to Present Abstracts from Ongoing Evaluations of Xyrem® (sodium oxybate) at SLEEP 2015


Sign up to receive e-mail alerts whenever Jazz Pharmaceuticals posts new information to the site. Just enter your e-mail address and click Submit.